PGNY — Progyny, Inc. Stock Price, Chart & AI Report

Positive Oct 8, 2026 • 09:16 UTC Zacks Investment Research • Na

Progyny (PGNY) Soars 6.3%: Is Further Upside Left in the Stock?

Progyny (PGNY) shares surged 6.3% following positive insights from its annual selling season, with the company expecting to add 1.2 million new covered lives through the first half of 2027. The fertility benefits provider is projected to report quarterly earnings of $0.51 per share (+13.3% YoY) and revenues of $339.72 million (+8.4% YoY). However, unchanged earnings estimate revisions over the past 30 days suggest the recent rally may lack sustained momentum.

PGNY AVTR fertility benefits covered lives earnings growth stock rally earnings estimates Zacks Rank

Sentiment note

Stock rallied 6.3% on strong annual selling season results with expectations to add 1.2 million new covered lives. Earnings and revenue growth projections are solid at +13.3% and +8.4% respectively. Carries Zacks Rank #2 (Buy).

Positive Oct 7, 2026 • 14:40 UTC Zacks Investment Research • Na

PGNY or CRL: Which Is the Better Value Stock Right Now?

A comparison of two Medical Services stocks reveals that Progyny (PGNY) presents a more attractive value investment opportunity than Charles River Laboratories (CRL). PGNY has a Zacks Rank of #2 (Buy) versus CRL's #3 (Hold), along with superior valuation metrics including a lower forward P/E ratio (12.40 vs 26.89) and a better Value grade (B vs D).

PGNY CRL value investing valuation metrics P/E ratio PEG ratio Zacks Rank Medical Services stocks

Sentiment note

PGNY demonstrates stronger fundamentals with a Zacks Rank #2 (Buy), lower forward P/E ratio of 12.40, PEG ratio of 1.07, and a Value grade of B, making it more attractive for value investors seeking undervalued stocks.

Positive Sep 18, 2026 • 15:40 UTC Zacks Investment Research • Na

PGNY vs. CRL: Which Stock Is the Better Value Option?

A comparison of two Medical Services sector stocks, Progyny (PGNY) and Charles River Laboratories (CRL), both with Zacks Rank #2 (Buy). Based on valuation metrics including forward P/E ratio (12.92 vs 24.87), PEG ratio (1.12 vs 2.76), and Value grades (B vs D), Progyny is identified as the superior value opportunity.

PGNY CRL valuation Medical Services P/E ratio PEG ratio value investing Zacks Rank

Sentiment note

Lower forward P/E ratio (12.92), lower PEG ratio (1.12), and stronger Value grade (B) indicate better valuation metrics and value opportunity compared to peer.

Positive Sep 15, 2026 • 13:15 UTC Zacks Investment Research • Zacks.Com

Concentra Group Holdings Parent, Inc. (CON) Hits Fresh High: Is There Still Room to Run?

Concentra Group (CON) has reached a new 52-week high of $36.05, gaining 82% year-to-date and outperforming its sector. The company maintains a Zacks Rank #1 (Strong Buy) with consistent earnings beat records and a VGM Score of B. However, valuation metrics show the stock trades at a premium to peers (21.7X forward P/E vs. 17X industry average), raising questions about further upside potential.

CON PGNY Concentra Group earnings surprise 52-week high valuation premium Zacks Rank #1 Medical Services industry

Sentiment note

Zacks Rank #2 (Buy) with strong earnings performance (7.84% beat), favorable VGM Score (B), and attractive forward P/E of 13.32X compared to CON. Positioned as a solid industry peer with better valuation.

Positive Aug 7, 2026 • 14:51 UTC GlobeNewswire Inc. • Not Specified

Progyny, Inc. to Present at the Canaccord Genuity Annual Growth Conference

Progyny, Inc. (Nasdaq: PGNY), a women's health and family building solutions company, announced that CEO Pete Anevski will present at the Canaccord Genuity 46th Annual Growth Conference in Boston on August 11, 2026. The company recently reported record quarterly revenue, gross profit, and adjusted EBITDA for Q2 2026, with strong demand continuing for its women's health and family building solutions.

PGNY women's health family building fertility solutions Q2 2026 results record revenue investor conference healthcare benefits

Sentiment note

The company reported record quarterly revenue, gross profit, and adjusted EBITDA. Additionally, robust selling season activity and strong demand for their solutions indicate healthy business momentum and growth trajectory.

Neutral Jun 25, 2026 • 17:05 UTC The Motley Fool • Robert Izquierdo

What Does the Sale of Progyny Shares by the CFO Mean for Investors?

Progyny CFO Mark Livingston sold 8,275 shares (9.47% of his direct holdings) for $211,000 on May 20, 2026, as part of a pre-arranged Rule 10b5-1 trading plan adopted in August 2025. The sale is not considered a red flag as it was non-discretionary. Despite losing a major customer, Progyny's shares rose in Q2 after the company provided strong 2026 guidance projecting 6-9% revenue growth, or 10-13% excluding the lost client's prior contributions.

PGNY insider trading CFO stock sale Rule 10b5-1 trading plan fertility benefits revenue guidance customer loss

Sentiment note

While the CFO's stock sale could appear negative, the article explicitly states it is not a red flag as it was part of a pre-arranged trading plan. The company's strong revenue guidance (6-9% growth, or 10-13% excluding one lost customer) and rising share price in Q2 offset concerns about the insider sale, resulting in a neutral overall assessment.

Positive May 11, 2026 • 14:57 UTC GlobeNewswire Inc. • Not Specified

Progyny, Inc. to Present at BofA Securities 2026 Health Care Conference

Progyny's CEO Pete Anevski and CFO Mark Livingston will participate in a fireside chat at the BofA Securities 2026 Health Care Conference on May 12, 2026. The company reported record first quarter 2026 revenue of $328.5 million, reflecting strong demand for women's health and family building solutions.

PGNY women's health family building fertility solutions healthcare conference Q1 2026 results record revenue employer benefits

Sentiment note

The company reported record first quarter revenue of $328.5 million and demonstrated robust demand for its solutions. Leadership participation in major healthcare conferences and multiple industry recognitions (TIME100, CNBC Disruptor 50, Forbes Best Employers) indicate strong market position and growth trajectory.

Positive Apr 23, 2026 • 17:55 UTC GlobeNewswire Inc. • Na

Progyny, Inc. Announces Details for Its First Quarter 2026 Results Report

Progyny, Inc. (Nasdaq: PGNY), a women's health and family building solutions company, announced it will report its Q1 2026 financial results on May 7, 2026, followed by a conference call. The company also announced the launch of the industry's first fully insured supplemental fertility plan for small employers, marking 10 years of operations in redefining women's health and family building care.

PGNY fertility benefits women's health family building supplemental insurance plan small employers Q1 2026 earnings conference call

Sentiment note

The company is announcing a milestone product launch (first fully insured supplemental fertility plan), celebrating 10 years of operations, and has received multiple industry recognitions (TIME100, CNBC Disruptor 50, Forbes Best Employers). The expansion of access to fertility benefits for small employers demonstrates business growth and market expansion.

Neutral Feb 12, 2026 • 19:46 UTC GlobeNewswire Inc. • Na

Progyny, Inc. Announces Details for Its Fourth Quarter and Full Year 2025 Results Report

Progyny, Inc. announced it will report its financial results for Q4 2025 and full year 2025 on February 26, 2026, after market close. The company will host a conference call at 4:45 p.m. ET to discuss results. A live webcast will be available on the company's investor relations website.

PGNY financial results Q4 2025 earnings call women's health family building fertility solutions

Sentiment note

The article is a factual announcement of upcoming earnings results and conference call details. No forward-looking statements, guidance changes, or performance metrics are disclosed that would indicate positive or negative sentiment. It is purely informational regarding the timing and logistics of the earnings announcement.

Positive Dec 2, 2025 • 23:16 UTC The Motley Fool • Josh Kohn-Lindquist

CEO Peter Anevski Buys $1.9 Million of Progyny Stock: Should Investors Buy Too?

Progyny's CEO Peter Anevski purchased 79,500 shares worth approximately $1.9 million, increasing his direct ownership to 680,251 shares. The purchase signals confidence in the company's performance, which has seen 9% sales growth and near-100% customer retention.

PGNY fertility benefits insider trading stock purchase healthcare services

Sentiment note

Strong financial performance, 60% total return in past year, continued sales growth, high customer retention, and CEO's significant stock purchase indicate positive company outlook

Positive Nov 7, 2025 • 18:02 UTC The Motley Fool • Josh Kohn-Lindquist

Why Progyny Stock Is Soaring Today

Progyny reported strong Q3 earnings with 9% sales growth and 23% adjusted growth, maintaining high client retention and demonstrating resilience after losing Amazon as a customer.

PGNY AMZN fertility women's health benefits management earnings stock performance

Sentiment note

Exceeded analyst expectations, showed 23% adjusted sales growth, maintained near-100% client retention, and has strong financial position with $300M cash and $200M stock buyback

Positive Apr 24, 2025 • 18:49 UTC GlobeNewswire Inc. • N/A

Progyny, Inc. Announces Details for Its First Quarter 2025 Results Report

Progyny, Inc. (PGNY) will report its Q1 2025 financial results on May 8, 2025, and host a conference call to discuss the results.

PGNY Progyny financial results conference call

Sentiment note

The article announces Progyny's upcoming financial results and conference call, which suggests the company is performing well and providing updates to investors.